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Background: Chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM) is a gene
family involved in multiple malignancies. CMTM4 is a member of this family and is located at chromosome 16q22.1,
a locus that harbours a number of tumour suppressor genes. It has been defined as a regulator of cell cycle and
division in HeLa cells; however, its roles in tumourigenesis remain poorly studied.
Methods: An integrated bioinformatics analysis based on the array data from the GEO database was conducted to
view the differential expression of CMTM4 across multiple cancers and their corresponding control tissues. Primary
clear cell renal cell carcinoma (ccRCC) and the paired adjacent non-tumour tissues were then collected to examine
the expression of CMTM4 by western blotting, immunohistochemistry, and quantitative RT-PCR. The ccRCC cell lines
A498 and 786-O and the normal renal tubular epithelial cell line HK-2 were also tested for CMTM4 expression by western
blotting. Cell Counting Kit-8 (CCK-8) and viable cell counting assays were used to delineate the growth curves of 786-O
cells after CMTM4 overexpression or knockdown. Wound healing and transwell assays were performed to assess the
cells’ ability to migrate. The effects of CMTM4 on cellular apoptosis and cell cycle progression were analysed by flow
cytometry, and cell cycle hallmarks were detected by western blotting and RT-PCR. The xenograft model in nude mice
was used to elucidate the function of CMTM4 in tumourigenesis ex vivo.
Results: By omic data analysis, we found a substantial downregulation of CMTM4 in ccRCC. Western blotting then
confirmed that CMTM4 was dramatically reduced in 86.9 % (53/61) of ccRCC tissues compared with the paired adjacent
non-tumour tissues, as well as in the 786-O and A498 ccRCC cell lines. Restoration of CMTM4 significantly suppressed
786-O cell growth by inducing G2/M cell cycle arrest and p21 upregulation, and cell migration was also inhibited.
However, knockdown of CMTM4 led to a completely opposite effect on these cell behaviours. Overexpression of CMTM4
also markedly inhibited the tumour xenograft growth in nude mice.
Conclusions: CMTM4 is downregulated and exhibits tumour-suppressor activities in ccRCC, and could be exploited as a
target for ccRCC treatment.
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Renal cell carcinoma (RCC) is the most prevalent malig-
nancy of the kidney, and it accounts for 2.4 % of all adult
malignancies [1]. Clear cell renal cell carcinoma (ccRCC)
represents the predominant histologic subtype of RCC
and constitutes approximately 80-90 % of all cases [1, 2].
Surgery is the most effective treatment of early and local
ccRCCs, but after the resection for local disease, 20–40 %
patients will develop recurrence [3], mainly due to the
tumour’s high resistance to both chemotherapy and radio-
therapy [2, 4]. Therefore, it is of paramount importance to
understand the molecular mechanisms underlying the
tumourigenesis of ccRCC. The identification of novel
genes that are functionally involved in the initiation and
progression of ccRCC may provide more sophisticated
early diagnostic and further therapeutic strategies.
The human chemokine-like factor (CKLF)-like MARVEL
transmembrane domain-containing family (CMTM) is a
gene family consisting of nine members, CKLF and
CMTM1-8 [5, 6]. Their encoded products are structurally
and functionally intermediate between classical chemo-
kines and the transmembrane-4 superfamily (TM4SF),
playing important roles in the immune system [7–11], the
male reproductive system [12–14] and tumourigenesis
[15–25]. Several members, such as CMTM3, 5, 7 and 8,
have been reported to exhibit tumour suppressor functions
in many types of malignancies, including gastric, pancre-
atic, liver, lung, cervical, oral, ovarian and oesophageal can-
cers [15–25].
CMTM4 is the most conserved member of this family
and forms a gene cluster with CKLF and CMTM1-3 on
chromosome 16q22.1, a locus that is frequently deleted or
modified in multiple tumours and that harbours a number
of tumour suppressor genes [26–33]. CMTM4 encodes
three transcript variants, CMTM4-v1, −v2 and -v3.
Among them, CMTM4-v2 is the full length cDNA prod-
uct and is highly conserved in most vertebrate animals
[34]. In HeLa cells, knockdown of CMTM4 can lead to
cell cleavage defects and binucleated cells after mitosis
[35], while overexpression of CMTM4-v1 and -v2 can in-
hibit cell growth by causing G2/M phase arrest without
inducing apoptosis [34]. These findings suggest that
CMTM4 might be an important gene involved in cell
growth and cell cycle regulation. However, the function of
CMTM4 in tumourigenesis remains poorly defined. In
this study, we analysed the expression pattern of CMTM4
using a bioinformatics strategy and focused on its expres-
sion and function in ccRCC.
Materials and methods
Bioinformatics
All of the array data related to cancers from the Affymetrix
human genome U133 plus 2.0 platform were downloaded
from the GEO database (http://www.ncbi.nlm.nih.gov/geo/),and a TumourProfile database (http://tumour.bjmu.e-
du.cn/, unpublished) has been developed to analyse the
differentially expressed genes in tumours using previ-
ously described data processing and microarray analysis
methods [36, 37]. The expression profile of CMTM4 in
a variety of cancers and the corresponding control (nor-
mal or non-tumour) tissues was searched in this data-
base, and the expression levels were represented as
average rank scores (ARS). Rank-based gene expression
(RBE) curves, which visually reflected the gene expres-
sion profile (GEP) across multiple tissues, were gener-
ated using the TumourProfile data set.Patient samples
A total of 61 patients with ccRCC (aged 22 to 78 years,
median age of 60 years) who underwent surgery between
January 2013 and April 2014 at the Department of
Urology, Peking University People’s Hospital (Beijing,
China) were enrolled in the present study. Paired
tumour and adjacent non-tumour tissues were collected
and tested for CMTM4 expression. All of the specimens
were pathologically confirmed. The paraffin-embedded
blocks of tumour tissues from each patient were assem-
bled from the archival collections at the Department of
Pathology. All participants gave informed consent ac-
cording to the Helsinki Declaration, and the protocol for
the present study was approved by the Ethics Committee
of Peking University People’s Hospital (Beijing, China).Cell lines, adenovirus and siRNAs
The ccRCC cell lines A498 and 786-O and the normal
renal tubular epithelial cell line HK-2 were routinely cul-
tured in MEM (Invitrogen, Carlsbad, CA, USA), RPMI-
1640 (HyClone, Logan, UT), and K-SFM medium (Gibco™
Life Technologies, Grand Island, NY) containing 10 % FBS
(HyClone) supplemented with 1 % penicillin/streptomycin,
respectively. All cells were grown at 37 °C in a humidified
incubator containing 5 % CO2. Adenoviruses carrying the
CMTM4 gene (Ad-CMTM4) and the empty adenovirus
(Ad-null) were packaged by AGTC Gene Technology Com-
pany, Ltd. (Beijing, China). The 786-O cells were infected
with the adenoviruses at an MOI of 100. Small interfering
RNAs (siRNAs) targeting CMTM4 were designed and
chemically synthesised by GenePharma Co., Ltd. (Suzhou,





negative control (si-NC), 5′-UUCUCCGAACGUGUCAC
GUTT-3′ (sense), 5′-ACGUGACACGUUCGGAGAATT-
3′ (antisense). 786-O cells were transfected with the
siRNAs using Lipofectamine™ 3000 (Life Technologies,
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instructions.
Protein extraction and western blotting
The cells were lysed in RIPA buffer (Sigma-Aldrich, St.
Louis, MO, USA) supplemented with a 1 % protease
inhibitor cocktail (Roche, Basel, Switzerland). The pro-
tein concentrations were determined using BCA protein
assays (Pierce, Rockford, IL, USA). The whole cell lysates
were then fractionated using 12.5 % or 15 % SDS–PAGE
gels and electrotransferred onto polyvinylidene difluoride
membranes (Hybond; GE Healthcare, Buckinghamshire,
United Kingdom). Western blotting was performed as
previously described [18]. The rabbit anti-CMTM4 pAb
was prepared in our lab [38]. The anti-cyclin B1, −cyclin
E, −cyclin-D1, −p21 and -p27 were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). β-actin blot-
ting was used as a lysate loading control. The density of
the bands was analysed by ImageJ software (National
Institutes of Health, Bethesda, Maryland, U.S.). The abso-
lute intensity of the target protein was normalised to the
absolute intensity of β-actin.
PCR and qPCR
The total RNAs were isolated from ccRCC tissues and cell
lines using TRIzol reagent (Invitrogen). Reverse transcrip-
tion was performed according to standard protocols using
a RevertAid™ II First Strand cDNA synthesis Kit (Thermo
Fisher Scientific Inc., Waltham, MA USA). Semiquantita-
tive and quantitative PCR (qPCR) were performed as
previously described [18]. GAPDH was amplified as an in-
ternal standard. The primers for PCR of CMTM4 were as
follows: CMTM4V2-F: 5′-CAGAAATTGCTGCCGTG
AT-3′, CMTM4V2-R: 5′-TGACTGAGAGACAGGCAC
G-3′, and the 72# probe (Roche) was used for qRT-PCR
of CMTM4. The primers for PCR of p21 were p21-F: 5′-C
TCAGAGGAGGCGCCATGTC-3′ and P21-R: 5′-TTAG
GGCTTCCTCTTGGAGAAG-3′.
Immunohistochemistry (IHC)
Immunohistochemical analysis was performed on formalin-
fixed, paraffin-embedded clinical tissues as previously de-
scribed [18]. A rabbit anti-CMTM4 pAb (4 mg/L) was used
as the primary antibody.
Cell proliferation assay
Cell proliferation was analysed using the Cell Counting
Kit-8 (CCK-8, Dojindo Laboratories, Kumamoto, Japan)
and viable cell counting assays. For the CCK-8 assays,
the cells were seeded in 96-well plates at a density of
3000 cells per well and then incubated at 37 °C in a 5 %
CO2 humidified atmosphere. At the indicated time
points, 10 μL CCK-8 solution was added into each well
and incubated for 2 h. The absorbance at 450 nm wasmeasured to assess the number of viable cells. The re-
sults were obtained from three independent experiments
in triplicate. For the viable cell counting assays, the cells
were seeded in 24-well plates at a density of 20,000 cells
per well. The viable cells marked by trypan blue exclu-
sion were counted using a Vi-CELL TM_XR Cell Viabil-
ity Analyzer (Beckman Coulter, Inc., Brea, CA, USA).
Flow cytometry
Cellular apoptosis was evaluated by FITC-conjugated
Annexin V/propidium iodide (PI) staining followed by
flow cytometry analysis, as previously described [18]. For
the cell cycle analysis, the cells were harvested 48 h after
infection with adenoviruses or transfection with siRNAs.
After washing with PBS, the cells were fixed in ice-cold
70 % ethanol overnight at −20 °C. The fixed cells were
then pelleted by centrifugation, washed twice in PBS,
and incubated in PBS containing 500 mg/mL RNase A
(Sigma-Aldrich) at 37 °C for 30 min. After staining with
10 mg/mL PI (Sigma-Aldrich) in 0.1 % Triton X-100, the
cells were collected on a BD FACSCalibur (BD
Bioscience, San Jose, CA, USA). The cell cycle distribu-
tion was analysed with the ModFit LT software (Verity
Software House, Topsham, ME).
Wound healing assay
The 786-O cells infected with Ad-CMTM4 or Ad-null
were cultured in 24-well plates until confluent. The cell
layer was then scratched using a sterile 10 μL micropipette
tip and washed twice with and subsequently maintained in
serum-free media. The cells were photographed 0, 24 and
48 h after wounding.
Cell migration assay
Forty-eight hours after infection or transfection, the
786-O cells were serum-starved for 6 h. Then, 3 × 104
cells in 250 μL serum-free media were seeded into the
upper chamber of a transwell with a fibronectin-coated
filter (8-mm pore size, Corning Life Sciences, NY, USA).
The bottom chamber contained medium supplemented
with 10 % FBS. After a 14-h (for the siRNA-transfected
cells) or 16-h (for the adenovirus-infected cells) incuba-
tion at 37 °C in a 5 % CO2 humidified atmosphere, the
nonmigrated cells were scraped off of the filter using a
cotton swab and the migrated cells were stained with
crystal violet following fixation with 4 % paraformalde-
hyde. The number of cells was counted in 8 randomly
chosen fields (magnification, ×200). Triplicate wells were
performed in each assay, and the assay was repeated at
least three times.
Xenograft model in nude mice
All protocols for the animal studies were reviewed and
approved by the institutional Animal Research Ethics
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ing 18–22 g) were maintained in a germ-free environment
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bThe P-values were calculated using the Wilcoxon rank-sum test in the R (http://ww
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respectively. The tumour diameter was measured with a
calliper every 3 days, and the tumour volume was calcu-
lated by length × width2 × 0.5. The mice were sacrificed at
day 27, when the tumours were dissected, weighed and
lysed for western blotting analysis.Statistical analysis
The bioinformatics analysis of the differences in
CMTM4 expression between the cancers and control
tissues were evaluated using the Wilcoxon rank-sum
test in the R (http://www.r-project.org/) software
environment. Bonferroni’s correction of the R function
“p.adjust” was used to adjust the P-values. The experi-
mental data were analysed using SPSS software 17.0
(SPSS, Inc., Chicago, IL, USA). CMTM4 expression was
correlated with the clinical characteristics using one-
way ANOVA (for the classification variables, such as
gender, stage and grade) or Pearson’s correlation ana-
lysis for two variables (for the continuous variables,
such as age). The differences between two independent
groups were analysed using Student’s t test. A P-value
< 0.05 was considered to represent a statistically signifi-
cant difference.Fig. 1 CMTM4 is downregulated at the mRNA level in ccRCC and brain can
used. In the rank-based gene expression (RBE) curves, the x-axis represents
indicates the sample percentiles at each rank scoreResults
CMTM4 is downregulated in ccRCC and brain cancers
according to the omic data analysis
Gene expression profiles can reveal essential clues regard-
ing a gene’s function. To assess the potential of CMTM4 as
a tumour suppressor, we performed an integrated bioinfor-
matics analysis based on the omic tumour data set from
the GEO database to determine the differential expression
of CMTM4 across multiple cancers and their correspond-
ing control (normal or non-tumour) tissues at the mRNA
level. The average rank scores (ARS), Bonferroni correction
adjusted P-values (Table 1), and rank-based gene expression
(RBE) curves (Fig. 1) were synthesised, and CMTM4 was
most significantly downregulated in ccRCC and several
brain cancers, such as neuroblastoma, glioblastoma, and
medulloblastoma, while no apparent differences were
observed in breast cancers, lung adenocarcinomas,
hepatocellular carcinomas (HCCs), etc. The downregula-
tion of CMTM4 in glioblastoma has been verified by a
recent study [25], and that in ccRCC is further supported
by the BioXpress (http://hive.biochemistry.gwu.edu/
tools/bioxpress) [40] and the protein atlas (http://
www.proteinatlas.org/ENSG00000183723-CMTM4/can
cer) databases. The BioXpress database indicates that
CMTM4 is downregulated in 95.83 % of ccRCC samplescers, according to bioinformatic analysis. The probe set 224998_at was
the expression intensity reflected by the rank scores, and the y-axis
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RNA sequencing (RNA-seq); the data set deposited in the
Cancer Genome Atlas (TCGA) from a total of 128 patients
has been collected and used for the analysis [40]. The pro-
tein atlas indicates that the CMTM4 protein is also
expressed at lower levels in renal cancer tissues (n = 12, in
general, weakly stained or negative) than in normal kidney
tissues (n = 2, moderately positive).
CMTM4 is frequently reduced in ccRCC tissues and cell lines
According to the bioinformatics analysis, we then exam-
ined CMTM4 expression in 61 paired ccRCC tissues and
adjacent normal tissues by western blotting. Compared
to the non-tumour tissue, CMTM4 was dramatically
downregulated in the ccRCC tissue. As the bands de-
tected in western blotting were identical to those for the
overexpressed CMTM4-v2 (~24 kDa, Fig. 3a), we fo-
cused on CMTM4-v2 in the subsequent studies, and the
term “CMTM4” was used to indicate “CMTM4-v2”. The
western blotting results of three representative pairedFig. 2 CMTM4 is frequently downregulated in ccRCC tissues and cell lines. a
tissues was detected by western blotting. The results of three representative p
relative CMTM4 expression level in all 61 patients was calculated for the t
the western blotting result and represented as a dot for each sample. CM
calculated fold change was less than 0.5 in the tumour tissue compared
further examined by immunohistochemistry (c) and qRT-PCR (d) in repres
tumour tissue was set as 1, and GAPDH was used as the internal control.
and the ccRCC cell lines 786-O and A498 was detected by western blottintissues are shown in Fig. 2a, and quantitative analysis of
the western blotting results of all 61 paired tissues was
performed by normalizing the band density of CMTM4 to
β-actin. The relative CMTM4 expression level was calcu-
lated for the tumour versus paired adjacent non-tumour
tissue. As shown in Fig. 2b, the expression of CMTM4
was frequently downregulated in ccRCC tissues (53/61,
86.9 %) compared to the matched adjacent non-tumour
tissues. We further analysed CMTM4 expression in repre-
sentative samples by immunohistochemistry and qRT-
PCR and obtained consistent results (Fig. 2c and d). Like-
wise, CMTM4 expression was also significantly lower in
the ccRCC cell lines (786-O and A498) than in the normal
renal tubular epithelial line HK-2 by western blotting
(Fig. 2e).
Correlations between CMTM4 expression and the clinical
features
We also analysed the association between multiple clin-
ical features of ccRCC patients and the expression ofCMTM4 expression in the tumour (T) and paired adjacent non-tumour (N)
aired tissues are shown. β-actin was used as an internal standard. b The
umour versus paired adjacent non-tumour tissue (T/N) according to
TM4 was considered to be significantly downregulated only if the
to the matched adjacent non-tumour tissue. CMTM4 expression was
entative samples. For qRT-PCR the CMTM4 expression level in the 2#
e CMTM4 expression in the normal renal tubular epithelial line HK-2
g. β-actin was used as an internal standard. N, normal kidney tissue
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CMTM4 expression levels and the parameters, including
age, gender, clinical stage, and histologic grade (Table 2).
CMTM4 inhibits 786-O cell growth
The reduced expression of CMTM4 in ccRCC prompted
us to determine whether it plays an inhibitory role in
tumourigenesis. The 786-O cells, in which CMTM4 was
expressed at low levels, were infected with a CMTM4-
expressing or empty adenovirus (Ad-CMTM4 or Ad-
null), and cell growth was monitored over a 96-h period.
The overexpression of CMTM4 was detected by western
blotting (Fig. 3a). The CCK-8 (Fig. 3b) and viable cell
counting (Fig. 3c) assays showed that CMTM4 significantly
inhibited the proliferation of 786-O cells compared with the
Ad-null infectants. Consistently with this finding, knock-
down of CMTM4 with two siRNAs (si-CMTM4-3 and 6) in
786-O cells (Fig. 3d) was more potent than the negative
control (si-NC) in promoting cell growth (Fig. 3e and f).
CMTM4 causes G2/M cell cycle arrest
To elucidate the mechanisms underlying the tumour cell
growth inhibition by CMTM4, its effects on apoptosis
and cell cycle progression were studied by flow cytome-
try. FITC-Annexin V/PI staining indicated that overex-
pression of CMTM4 did not induce apoptosis of 786-O
cells 72 h after infection (Fig. 4a). However, the Ad-
CMTM4-infected cells had a significant increase in the
G2/M phase population compared with the Ad-null
infectants (Fig. 4b). We further examined several key cell
cycle regulators by western blotting and found that p21
expression was upregulated in the CMTM4-expressingTable 2 Correlations between CMTM4 expression and the clinical fe
Clinical factors Sample size Mean ratio, T/N ±
Gender
Male 39 0.290 ± 0.318








1 27 0.182 ± 0.039
2 26 0.282 ± 0.050
3 2 0.567 ± 0.313
aThe relative CMTM4 expression level was calculated from the tumour (T) versus pa
bThe P-value was calculated using one-way ANOVA (for the classification variable
variables (for the continuous variables, such as age)
cn.a. indicates not available due to a small sample size
dThe tumour stage was defined according to TNM (International Union Against Can786-O cells compared with the controls, whereas p27
and Cyclin B1, E and D1 were unaffected (Fig. 4c). RT-
PCR was then performed and demonstrated that p21
expression was also upregulated at the mRNA level
(Fig. 4d). However, knockdown of CMTM4 reduced the
G2/M phase accumulation (Fig. 4e) and p21 expression at
both the protein and mRNA levels (Fig. 4f and g). These
results suggested that CMTM4 induces cell cycle arrest at
the G2/M phase by upregulating p21 in 786-O cells.
CMTM4 inhibits 786-O cell migration
Migration is another important aspect of tumourigenesis
and has been reported to be negatively regulated by p21
[41]. We then explored the impact of CMTM4 on
ccRCC cell migration. Wound-healing assays were first
performed, and wound closure was found to be retarded
for CMTM4-overexpressing 786-O cells (Fig. 5a). Trans-
well assays were then conducted to evaluate the motility
of CMTM4 overexpressing or knockdown 786-O cells.
Compared with their respective controls, overexpression
of CMTM4 led to a significant decrease in the number
of migrated cells (Fig. 5b), while knockdown of CMTM4
increased the number of 786-O cells that crossed over
the filter (Fig. 5c).
CMTM4 suppresses tumour growth ex vivo
The in vitro experiments demonstrated that CMTM4
exhibited antitumourigenic activities in ccRCC; there-
fore, we subsequently used a xenograft model in nude
mice to confirm the ex vivo tumour-suppressor activity
of CMTM4. 786-O cells infected with Ad-CMTM4 or
Ad-null were injected subcutaneously into the right andatures of the ccRCC patients






ired adjacent non-tumour tissue (N)
s, such as gender, stage and grade) or Pearson correlation analysis for two
cer, 6th edition, 2002)
Fig. 3 CMTM4 inhibits 786-O cell growth. a Overexpression of CMTM4 by infection with a CMTM4-expressing adenovirus (Ad-CMTM4) was
confirmed by western blotting. The empty adenovirus (Ad-null) was used as a control. The Cell Counting Kit-8 (b) and viable cell counting
(c) assays showed that cell growth was inhibited by overexpression of CMTM4 in 786-O cells. The results are expressed as the means ± SEM
of three independent experiments in triplicate. *, P < 0.05; **, P < 0.01; and ***, P < 0.001 compared to the controls at each time point. d
Knockdown of CMTM4 with two siRNAs (si-CMTM4-3 and 6) in 786-O cells was verified by quantitative RT-PCR (upper panel) and western
blotting (lower panel). si-NC, negative control siRNA. The CMTM4 expression levels were measured relative to the level in the si-NC transfected cells in
quantitative RT-PCR. The Cell Counting Kit-8 (e) and viable cell counting (f) assays showed that cell growth was promoted by knockdown of CMTM4 in
786-O cells. The results are expressed as the means ± SEM of three independent experiments in triplicate
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peared approximately one week after implantation.
Within 4 weeks, the volume and weight of tumours from
the CMTM4 overexpressing cells were significantly
smaller than those of the controls (Fig. 6a-c). We also
detected the expression of p21 in the tumour xenografts
by western blotting and found that it was decreased in
the CMTM4 overexpressing tumours (Fig. 6d). These
data confirmed that CMTM4 exhibits tumour suppres-
sor activities in ccRCC.
Discussion
The tumour suppressor functions of members of the
CMTM family, particularly CMTM3, 5, 7 and 8, have been
extensively studied in multiple types of malignancies. In
contrast, CMTM4 remains less investigated. A compre-
hensive analysis of CMTM4 expression across multiple
cancers using bioinformatics indicated that CMTM4 is
most significantly downregulated in brain cancers and
ccRCC, which implies a tissue-specific function of
CMTM4. Currently, omic data analysis has become a
major trend in numerous fields, among which gene
expression profile (GEP) analysis is generally an essen-
tial step in functional gene studies. Analyses usingother databases, as well as Delic S. and colleagues’ [25]
and our experimental data, demonstrate the viability of
our analysis method [37] in GEP predictions, with high
efficiency and accuracy.
Using a total of 61 paired ccRCC tissues and adja-
cent normal tissues, we show that CMTM4 expression
is frequently downregulated in renal cancer tissues.
However, the expression levels of CMTM4 were not
correlated with the patients’ gender and age. Because
surgical resection is restricted to early and local
ccRCCs, most patients are at stage one and histologi-
cally exhibit high and moderate differentiation (grade
I and II). Therefore, this correlation was not available
due to the limitation of the clinical samples. Moreover,
the survival data are still being collected, because most
of the patients had undergone surgical resection only
a short time ago.
CMTM4 is tightly linked with CMTM1-3 on chromo-
some 16q22.1, a genomic region prone to both genetic
and epigenetic modifications in various cancers. Chromo-
somal aberrations, such as deletions, amplifications
[26–29], single nucleotide polymorphisms (SNPs) [30],
loss of heterozygosity (LOH) and microsatellite instabil-
ity (MSI) [31, 32], as well as aberrant methylations [29],
Fig. 4 CMTM4 induces G2/M cell cycle arrest. a Annexin V/PI-staining indicated that overexpression of CMTM4 did not induce apoptosis of 786-O
cells 72 h after infection. Shown is a representative result of three independent experiments. b The cell cycle was analysed 48 h after infection of
786-O cells by flow cytometry. Representative histograms (left) and the percentage of cells at the different phases (right) are shown. The data are
expressed as the means ± SEM of three independent experiments. **, P < 0.01. c Western blotting analysis of cell cycle hallmarks in infected 786-O
cells. β-actin was used as an internal standard. A representative result and the means of the relative intensities of the target proteins averaged for
the three independent experiments are shown with the SEM. ***, P < 0.001; ns, not significant. d RT-PCR of p21 at 24 h after infection of 786-O cells.
GAPDH was used as an internal standard. The grey density of the target bands was analysed by ImageJ software (National Institutes of Health,
Bethesda, Maryland, U.S.) and normalised to the grey density of GAPDH. The average relative grey density with the SEM is shown from three independent
experiments. Knockdown of CMTM4 reduced the G2/M phase accumulation (e) and p21 expression at both the protein (f) and mRNA levels (g). **, P< 0.01;
and ***, P<0.001
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lignancies. Our previous studies have also shown that
CMTM3 is frequently inactivated by promoter CpG
methylation [18]. It remains to be clarified whetherthese mechanisms are also involved in the downregula-
tion of CMTM4 in ccRCC.
Regular cell cycle progression is a key factor in cell pro-
liferation, and alterations of the cell cycle may influence
Fig. 5 CMTM4 inhibits 786-O cell migration. a Representative images (magnification, ×100) of adenovirus-infected 786-O cell migration in the
wound-healing assay were photographed at 0, 24 and 48 h after scratching (left). The relative migration rate was calculated by dividing the
change in the distance between the scratch edges by the initial distance (right). Transwell assays (magnification, ×100) were performed to
evaluate the migration of adenovirus-infected (b) and siRNAs-transfected (c) 786-O cells. The statistical graph indicates the means ± SEM of the
number of cells from 8 random high power fields (magnification, ×200) counted from three independent experiments
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ant regulator of cell cycle progression and division in
HeLa cells [34, 35]. Here, we also observed that overex-
pression of CMTM4 inhibited 786-O cell growth by indu-
cing G2/M phase accumulation. p21 was increased in the
process, which plays complex roles in tumourigenesis by
regulating the cell cycle, senescence, apoptosis and migra-
tion [41]. Through its interaction with the Cdk1/CyclinB
complex, the p21 protein interferes with the transition of
cells from the G2 phase of the cell cycle into mitosis;moreover, by inhibiting the Rho cascade, p21 can also
influence cytoskeletal factors and cell motility [41].
Therefore, the upregulation of p21 may be responsible
for the tumour suppressor functions of CMTM4 in
786-O cells. However, increased p21 expression is not
necessarily linked to growth arrest; thus, the sophisti-
cated mechanism underlying the inhibitory activities of
CMTM4 is still to be explored. On the other hand, p21
is well known to be induced by p53. In addition, several
p53-independent pathways have also been identified
Fig. 6 CMTM4 inhibits the tumourigenicity of 786-O cells ex vivo. a A representative nude mouse (left) showing the different morphologies of the
tumours derived from the Ad-CMTM4-infected 786-O cells and Ad-null-infected control cells. The tumours were then dissected and photographed
(right). The growth curve (b) and average weight (c) of the CMTM4-expressing tumours versus the control tumours are expressed as the means ± SEM
for each group (n = 6). *, P < 0.05; **, P < 0.01; and ***, P < 0.001. d The expression of CMTM4 and p21 in the tumour xenografts was detected
by western blotting. β-actin was used as an internal standard. A representative result of the tumours from one mouse (left) and the average
relative intensity of p21 with the SEM from 6 mice (right) are shown. *, P < 0.05
Li et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:122 Page 11 of 13[42]. Overexpression of CMTM4 increased p21 not
only at the protein level but also at the mRNA level,
whereas knockdown of CMTM4 decreased both. How-
ever, because p53 is inactive in 786-O cells [43], the
mechanism by which CMTM4 regulates p21 and
whether it influences the transcription or the degrad-
ation of the p21 mRNA requires further investigation.Conclusions
In summary, CMTM4 is frequently reduced in ccRCC
tissues and cell lines, according to omic data analysis as
well as our experimental data. Restoration of CMTM4
suppresses the tumourigenicity of 786-O cells both
in vitro and ex vivo, whereas knockdown of CMTM4 led
to promoting effects. These observations highlight the
Li et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:122 Page 12 of 13potential of CMTM4 as a tumour suppressor in ccRCC.
A better understanding of the roles of CMTM4 in
tumourigenesis may allow researchers to develop novel
diagnostics and more effective treatment strategies for
this malignancy.
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